Lupin Wins FDA Nod for Risperidone

  Published 7 months ago

Lupin gained USFDA approval for Risperidone LAI, leveraging Nanomi technology, securing 180-day CGT exclusivity.

  • Risperidone LAI treats schizophrenia, bipolar I disorder and is bioequivalent to Risperdal Consta long-acting injection.
  • Lupin’s first Nanomi-based product approval validates its LAI platform, strengthening its specialty injectables pipeline and innovation strategy.
  • IQVIA reported annual US sales for Risperidone extended-release injectable suspension estimated at $190 million.

You might like these

Maithan Alloys Invests in GAIL India Shares for Strategic Growth

Renault Appoints New India CEO

Adani Power wins Assam coal bid

Air India Flight Makes Emergency Landing in Thailand Over Bomb Threat

Rupee Hits Record Low Ahead of RBI Policy

India's Data Quality Boost: Niti Aayog's New Tools

India’s August Private Sector Boom

News that matters the most ⚡